Zealand Pharma has shared positive Phase I multiple ascending dose (MAD) topline results for the company’s novel Kv1.3 ion channel blocker, ZP9830. The MAD part of the first-in-human, single-centre, randomised, double-blind, placebo-controlled Phase I trial was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple… Read More
Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More
Zealand Pharma and OTR Therapeutics have entered a multi-programme strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases. The collaboration will combine Zealand Pharma’s experience in obesity and metabolic health with OTR Therapeutics’ oral small-molecule platform. “The multi-programme collaboration will expand our… Read More
New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. The findings were presented at the 2023 American Diabetes Association’s… Read More
